Trial reportOpen forum infectious diseases2024
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- HIV cure after HCT: 7 horses seem to be on the mark.Blood advances · 2026Article
- Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration.Frontiers in immunology · 2026Review
- Understanding the HIV-specific T-cell response to immune checkpoint blockade: what can we learn from cancer immunotherapy?Current opinion in HIV and AIDS · 2025Review
- Impacts of immune checkpoint inhibitors use on the HIV reservoir are linked to provirus sequences but not integration sites.Scientific reports · 2025Article
- Clinical and experimental treatment of residual immune activation in people living with HIV.Clinical and experimental immunology · 2025Review
- Influence of PD-1 and PD-1L Immune Exhaustion Receptors on Immune Reconstruction in People Living With HIV.Journal of immunology research · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 13 institutions in 1 country.
Cynthia L GayDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-3620-3059
Ronald J BoschDepartment of Biostatistics, Center for Biostatistics and AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-1774-4140
Ashley McKhannDepartment of Biostatistics, Center for Biostatistics and AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Raymond ChaCenter for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID https://orcid.org/0000-0001-6302-3881
Gene D MorseCenter for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, New York, USA.ORCID https://orcid.org/0000-0001-6758-0941
Chanelle L WimbishDepartment of Clinical Research, Social and Scientific Systems, Inc, a DLH Company, Silver Spring, Maryland, USA.
Danielle M CampbellDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Kendall F MoseleyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-2500-2312
Steven HendrickxDepartment of Medicine, University of California, San Diego, San Diego, California, USA.
Michael MesserDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0009-0004-3161-1549
Constance A BensonDepartment of Medicine, University of California, San Diego, San Diego, California, USA.ORCID https://orcid.org/0000-0002-3781-1347
Edgar T OvertonDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-4013-536X
Anne PaccalyDepartments of Clinical Sciences, Translational Medicine and Precision Medicine, Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.ORCID https://orcid.org/0000-0003-0892-9079
Vladimir JankovicDepartments of Clinical Sciences, Translational Medicine and Precision Medicine, Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.ORCID https://orcid.org/0000-0002-4135-8629
Elizabeth MillerDepartments of Clinical Sciences, Translational Medicine and Precision Medicine, Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.
Randall TresslerHIV Research Branch, Division of AIDS, National Institute of AIDS, National Institutes of Health, Rockville, Maryland, USA.
Jonathan Z LiDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-6196-5883
Bernard J C MacatangayDivision of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-0405-0991
Joseph J EronDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-4938-0644
W David HardyDivision of Infectious Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-8948-9524
A5370 Team
Regeneron (United States) · USBrigham and Women's Hospital · USCancer Research And Biostatistics · USUniversity at Buffalo, State University of New York · USUniversity of Alabama at Birmingham · USUniversity of California San Diego · USUniversity of North Carolina at Chapel Hill · USJohns Hopkins University · USNational Institutes of Health · USSocial and Scientific Systems (United States) · USUniversity of California, Los Angeles · USUniversity of Pittsburgh · USUniversity of Southern California · US
Funding
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MUniversity of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8MHarvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2MUCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4MNorth Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9MUniversity of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0MNorth Carolina Translational and Clinical Sciences Institute (NC TraCS)UM1TR004406 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NICHOLAS J SHAHEEN · 2023 to 2026
$37.5MNCATS NIH HHS UL1 TR001111NCATS NIH HHS UM1 TR004406NIAID NIH HHS P30 AI050410NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069494
Abstract
Background: T cells in people with human immunodeficiency virus (HIV) demonstrate an exhausted phenotype, and HIV-specific CD4 Methods: This was a phase 1/2, randomized (4:1), double-blind, placebo-controlled study in adults with suppressed HIV on antiretroviral therapy with CD4 Results: Five men were enrolled (median CD4 Conclusions: One of 4 participants exhibited increased HIV-1
Indexed as
anti-PD-1 inhibitorHIVHIV cureHIV latencyimmune checkpoint inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.